• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.10a
• /
• pp.751-752
• /
• 2005

• The Korean Journal of Nuclear Medicine
• /
• v.1 no.1
• /
• pp.67-78
• /
• 1967

Over the past 6 years, from May 1960 to June 1966, 1,716 patients with various diseases of thyroid were examined and thyroid function tests with $^{131}I$ were done. Among them, 545 patients with hyperthyroidism were treated with $^{131}I$. A summary of the clinical data of the $^{131}I$-thyroid function tests and the therapeutic results of $^{131}I$ were presented and discussed. 1. The patients examined consisted of; 596 cases(34.7%) with toxic diffuse goiter, 412 cases(24.0%) with non-toxic nodular goiter, 278 cases(16.2%) with euthyroidism, 236 cases(13.8%) with non-toxic diffuse goiter, 89 cases(5.2%) with hypothyroidism, 53 cases(3.1%) with toxic nodular goiter, 32 cases(1.9%) with thyroiditis and 20 cases(1.2%) with dyshormonogenesis. 2. There were 218(12.7%) male patients and 1,498(87.3%) female patients, showing a ratio of 1:6.9. female predominantly. 3. The majority of patients(79.6%) were in the 3rd through 5th decades of their lives showing the peak in the 4th decades(35.9%). 4. The diagnostic values and normal ranges of $^{131}I$ uptake test, 48 hour serum activity, $T_3$ red blood cell uptake and $PB^{131}I$ conversion ratio were discussed. 5. An attention was given to dyshormonogenesis, a qualitative hypothyroidism, due to its characteristic findings of clinical and $^{131}I$ thyroid function tests, and its pathogenesis was briefly reviewed. 6. Among 545 patients with hyperthyroidism treated with $^{131}I$, 68.3% was cured after single. therapeutic dose and another 24.0% was cured after second dose. 7. The complications of $^{131}I$ therapy were discussed in some details and myxedema had developed. in 3.9% of our cases. No thyroid cancer was found after $^{131}I$ therapy.

• Radioisotope journal
• /
• v.21 no.3
• /
• pp.46-60
• /
• 2006

In recent years the progress of nuclear medicine advanced dramatically in imaging and targeted radionuclide therapy is able to open op exciting perspectives as standard diagnostic and therapeutic modalities, complementing conventional modalities. Positron emission tomography/computed tomography (PET/CT) technology with FDG has been developed clinically in less than 10 years as a routine standard in oncological imaging, including a number of other fluorinated radiopharmaceuticals being evaluated for their ability to complement FDG. However, the limitation of FDG-PET such as non-specific uptake and its short half-life is not compatible with the time necessary for optimal tumour targeting. Therefore, a development of innovative positron-emitting radionuclides with half-lives longer than 10 h is needed. For therapeutic applications, the injection of higher activities is required to reach efficient adsorbed doses in radioresistant solid tumours, while limiting the irradiation of vital organs. In this application, the longer half-life of radiolsotopes are more fit well for radionuclide therapy. To achieve this, researches have to be carried in a largor spectrum of radionuclides for diagnosis and therapy. In the context of rapidly growing nuclear medicine and strong demanding innovative radionuclides, a high-energy (100 MeV), high-intensity (-mA) accelerator with proton (PEFF at KAFRI). will be operating in 2011. The priorities of PEFP will include supporting the nuclear medicine research community by providing those radionuclides with current limited availability by means of a high-energy, high-intensity accelerator.

• Journal of radiological science and technology
• /
• v.45 no.5
• /
• pp.433-438
• /
• 2022

Targeted radionuclides treatment (TRT) requires the establishment of treatment plans that consider various factors, such as the type of radionuclides, target organs, and administration methods. For this reason, in this study, the absorption dose of a single cell was analyzed according to the type of radioisotope used to treat target radionuclides. In this study, a simulation was performed on beta rays used in the treatment of target radionuclides at the cell level using MCNPX (ver. 2.5.0). First, according to the calculation formula, the beam path according to the type of radioisotope for treatment was calculated. Second, the amount of self-radiation by beta rays emitted from cell diameters of 5 ㎛ and 10 ㎛ cell nuclei was evaluated. As a result, it showed a high range proportional to the maximum energy of the beta-ray, and the highest self-dose distribution from 177 Lu radiation sources among therapeutic radioisotopes. This was analyzed as a result that is inversely proportional to the maximum energy of the beta-ray, and it suggests that the selection of a nuclide considering the range of the beta-ray is necessary in the treatment of target radionuclides in the future.

• Journal of Welding and Joining
• /
• v.27 no.1
• /
• pp.65-70
• /
• 2009

Ir-192 radiation sealed sources are widely employed to the therapeutic applications as well as the non-destructive testing. Production of Ir-192 sources requires a delicate but robust welding technique because it is employed in a high radioactive working environment. A GTA(Gas Tungsten Arc) welding technique is currently well established for this purpose. However, this welding method requires a frequent replacement of the electrode, which results in the delay of the production to take a preparatory action such as to isolate the radiation sources from the working place before getting access to the welding machine. Hence, a resistance welding technique is considered as an alternative method of the GTA welding technique. The advantages of resistance welding are high welding speed and high-rate production. Also it has very long life of electrode comparing to GTA welding. In this study, the resistance welding system and proper welding conditions were established for sealing Ir-192 source capsule. As a results of various experiments, it showed that electrode displacement can be employed as a indicator to predict welding quality. We proposed two mathematical models(linear and curvilinear) to estimate electrode displacement with process parameters such as applied force, welding current and welding time by using regression analysis method. Predicting results of both linear and curvilinear model were relatively good agreement with experiment.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.6 no.1
• /
• pp.46-52
• /
• 2020

Radiopharmaceuticals that can be consumed in specific disease site play a key role In order to diagnose and treat the diseases. In addition, radiopharmaceuticals can be used for diagnostic or therapeutic purposes depending on the type of the labeled radioactive isotope. Recently, theragnostic radiopharmaceuticals that can simultaneously diagnose and treat are developed. Therefore, the development of target-specific radiopharmaceuticals is a very important research topic in the field of molecular imaging and therapy. This review paper summarizes the basic considerations for the development of radiopharmaceuticals. For new researchers or students who are now beginning in the field of radiopharmaceuticals, we intend to assist in the development of radiopharmaceuticals by describing the definition of radiopharmaceuticals, the ideal radiopharmaceutical conditions, the considerations for developing new radiopharmaceuticals, the factors affecting the design of radiopharmaceuticals, the requirements of radioisotope labeling reactions, and finally the definition and importance of molar activity in radiopharmaceuticals.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.8 no.2
• /
• pp.139-150
• /
• 2022

Theranostics, a composite word of therapy and diagnosis, is known as personalized medicine and the concept of diagnosis and treatment at the same time. In nuclear medicine, it means performing both therapeutic and diagnostic radioisotope therapy using the same target molecule. The increased production and utilization of ⁶⁴Cu opens a new era of theranostics. The studies introduced here have shown that ⁶⁴CuCl₂ and various compounds or biomolecules labeled with ⁶⁴Cu are unique radiopharmaceuticals with physiological properties suitable for use as diagnostic and therapeutic agents. So far, these two abilities have been described only for radioactive iodine. Although ⁶⁴Cu has complex chemical properties compared to other PET radioisotopes such as ⁶⁸Ga, it has an appropriate half-life and enables high-quality PET images similar to ¹⁸F, which is an advantage in terms of diagnosis. In addition, since it also has therapeutic properties through the release of β^- particles and Auger electrons by electron capture, radiopharmaceuticals using ⁶⁴Cu stand for innovative radiopharmaceuticals for theranostic purposes. Therefore, based on the initial results obtained using ⁶⁴Cu as a therapeutic agent, it is expected that additional research on the application of ⁶⁴Cu will lead to a new era in the theranostics field.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.2
• /
• pp.164-171
• /
• 2008

Medical internal radiation dosimetry (MIRD) is an important part of nuclear medicine research field using therapeutic radioisotope. There have been many researches using MIRD for the development of new therapeutic approaches including radiopharmaceutical, clinical protocol, and imaging techniques. Recently, radionuclide therapy has been re-focused as new solution of intractable diseases, through to the advances of previous achievements. In this article, the basic concepts of radiation and internal radiation dosimetry are summarized to help understanding MIRD and its application to clinical application.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.9 no.1
• /
• pp.35-41
• /
• 2023

Photodynamic therapy (PDT), in which a photosensitizer (PS), light, and molecular oxygen are essential components, is a non-invasive and highly effective cancer therapeutic method. However, PDT suffers from the penetration limit of light caused by attenuation and scattering of light through tissues constraining its use to skin and endoscopically accessible cancers. Cerenkov luminescence (CL) is defined as the light illuminated when charged particles move in a dielectric medium at a velocity greater than the phase velocity of light. It is known that medical radioisotopes in preclinical and clinical settings have enough energy to generate CL, and lately, CL has been exploited as an excitation source for PDT without external light illumination. This review introduces state of the art studies of radioisotope-based PDT for cancer, in which radioisotopes are utilized as a light source.

• Journal of Radiation Protection and Research
• /
• v.15 no.2
• /
• pp.113-122
• /
• 1990

After four years of planning, equipment acquisition, facility construction and beam testing, the KCCH cyclotron facility was put into operation in November1986. Now the KCCH cyclotron(MC-50) has been used for four years in neutron therapy and radioisotope production. Up to December 1989, 179(1852 sessions) patient have undergone neutron therapy. Radioisotope production for nuclear medicine use was started from March 1989 after extensive work to overcome target transport, target melting, beam diagnostic and chemical processing problems. This status report introduces the cyclotron facility, and the experiences of neutron therapy and isotope production with the MC-50 cyclotron. Besides, the operation results and the general troubles of the MC-50 during 1989 are summarized. Total operation time was 1252.5 hours. Four hundred hours were used for neutron therapy of 599 treatment sessions and 832.5 hours for radioisotope production. Total amount of produced raioisotope was 1695 mCi(Ga-67 : 1478mCi, Tl-201 : 107 mCi, I-123 : 25mCi, In-111 : 85mCi). Twenty hours were used for scheduled beam testing. In 1989, 882% of the planned operation were performed on schedule and this rats is improved remarkably compared to 71.0% in 1988.